News

Business will become part of Thermo Fisher’s Analytical Instruments Segment.

WaveSense's cell enrichment technology platform has received CE-IVD marking approval.

Foundation Medicine will identify individuals with non-hodgkin lymphoma whose tumors possess EZH2 mutations for potential enrollment into Epizyme's Phase 2 clinical trial.

New molecular assay is only commercial test to detect both M. genitalium and antibiotic resistance for one of the world’s fastest spreading STD.

The partnership is set up to provide ultra-fast bioinformatics software designed for use with the new Rubicon ThruPLEX® Tag-seq kits.

Eleven Biotherapeutics, Inc. to acquire Viventia Bio Inc. to create targeted protein therapeutics oncology company.

Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.

Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.

UC Berkeley, UC San Francisco and Stanford University collaborate on research funded by a $600 million investment from Mark Zuckerberg and Priscilla Chan.

Allergan has acquired Akarna Therapeutics for $50 million, the second of NASH related purchases this week.